Kalaris Therapeutics, Inc. (KLRS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-210M -140M -70M 0 70M 140M 210M Q4 '19: -26.7M Q1 '20: -33.8M Q2 '20: -40M Q3 '20: -55.4M Q4 '20: -71.3M Q1 '21: -92.3M Q2 '21: -117.8M Q3 '21: -139.4M Q4 '21: -169.8M Q1 '22: -182.1M Q2 '22: -189.1M Q3 '22: -186.6M Q4 '22: -171.2M Q1 '23: -171.2M Q2 '23: -173.9M Q3 '23: -177.9M Q4 '23: -199.9M Q1 '24: -159.2M Q2 '24: -116.1M Q3 '24: -107M Q4 '24: -51.7M Q1 '25: -59.5M Q2 '25: -67.6M Q3 '25: -42.5M Q4 '25: -46.2M Q1 '26: -47.6M Q2 '26: -47.8M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-210M -140M -70M 0 70M 140M 210M Q4 '19: -23.8M Q1 '20: -30.7M Q2 '20: -37M Q3 '20: -53.3M Q4 '20: -69.8M Q1 '21: -91.4M Q2 '21: -117.3M Q3 '21: -139.2M Q4 '21: -172M Q1 '22: -184.9M Q2 '22: -192M Q3 '22: -188.5M Q4 '22: -168.7M Q1 '23: -166M Q2 '23: -166.7M Q3 '23: -168.9M Q4 '23: -190.4M Q1 '24: -152.6M Q2 '24: -113M Q3 '24: -106.8M Q4 '24: -69.2M Q1 '25: -76M Q2 '25: -81.7M Q3 '25: -55.5M Q4 '25: -43.4M Q1 '26: -44.1M Q2 '26: -44.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q2 '20: -36.9M Q3 '20: -48.6M Q4 '20: -60.8M Q1 '21: -69.2M Q2 '21: -81M Q3 '21: -99.3M Q4 '21: -106.3M Q1 '22: -133.9M Q2 '22: -139.9M Q3 '22: -138.5M Q4 '22: -142.1M Q1 '23: -127.7M Q2 '23: -125.9M Q3 '23: -125.3M Q4 '23: -124.5M Q1 '24: -96.9M Q2 '24: -73.7M Q3 '24: -43.6M Q4 '24: -20.7M Q1 '25: -23.6M Q2 '25: -32.2M Q3 '25: -39.2M Q4 '25: -38.4M Q1 '26: -42.5M Q2 '26: -41M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '21: 62.3M Q3 '21: 63M Q1 '22: 64M Q2 '22: 64.5M Q3 '22: 84.9M Q1 '23: 93.3M Q2 '23: 94.6M Q3 '23: 113.9M Q1 '24: 1.3M Q2 '24: 1.3M Q3 '24: 1.4M Q1 '25: 4.1M Q2 '25: 18.7M Q3 '25: 18.7M Q1 '26: 23.7M Q2 '26: 23.8M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-90.00 -60.00 -30.00 0.00 30.00 60.00 90.00 Q4 '19: -18.54 Q1 '20: -19.10 Q2 '20: -18.48 Q3 '20: -14.09 Q4 '20: -2.59 Q1 '21: 1.12 Q2 '21: 4.95 Q3 '21: 4.81 Q4 '21: -2.74 Q1 '22: -2.93 Q2 '22: -3.02 Q3 '22: -2.80 Q4 '22: -2.25 Q1 '23: -2.00 Q2 '23: -1.79 Q3 '23: -1.68 Q4 '23: -42.10 Q1 '24: -44.26 Q2 '24: -48.04 Q3 '24: -75.81 Q4 '24: -51.35 Q1 '25: -51.27 Q2 '25: -47.62 Q3 '25: -20.10 Q4 '25: -4.21 Q1 '26: -2.15 Q2 '26: -2.02 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.